{"id":32,"slug":"32-bpc-157-c-terminal-fragment-truncation-retain-only-residues-10-15-dd","title":"BPC-157 truncation: minimal C-terminal pentapeptide DDAGLV for VEGFR2 engagement","status":"PROMISING","fold_verdict":"PROMISING","discard_reason":null,"peptide":{"name":"BPC-157","class":"REGENERATIVE","sequence":"GEPPPGKPADDAGLV","modified_sequence":"DDAGLV","modification_description":"C-terminal fragment truncation: retain only residues 10-15 (DDAGLV), removing the N-terminal GEPPPGKPA segment to isolate the putative VEGFR2-interacting acidic/hydrophobic motif"},"target":{"protein":"Vascular endothelial growth factor receptor 2","uniprot_id":"P35968","chembl_id":"CHEMBL279","gene_symbol":"KDR"},"rationale":{"hypothesis":"We hypothesize that the C-terminal hexapeptide DDAGLV of BPC-157 contains the minimal pharmacophore responsible for VEGFR2 engagement, with the tandem aspartates (D10-D11) mimicking acidic VEGF-A loop residues that contact the Ig-domain interface. Truncating away the proline-rich N-terminus (GEPPPGKPA) should remove a flexible, possibly non-contributing scaffold and produce a smaller, higher-affinity-per-mass binder. We will test whether the isolated fragment retains a defined extended conformation suitable for receptor docking.","rationale":"The N-terminal PPPGKP stretch of BPC-157 is conformationally flexible and likely acts as a spacer rather than a contact element, while the DDAGLV C-terminus contains the only acidic residues in the peptide and a small hydrophobic GLV tail — features that resemble VEGF receptor-binding loop chemistry. Fragment/truncation studies are the most direct way to localize a pharmacophore in a peptide with no published bound structure. This diverges from the last 3 lab folds (Aib substitutions and a stapled peptide on other peptides) by using a fragment/truncation category and an AFFINITY focus, neither of which appear in folds #29-31.","predicted_outcome":"AlphaFold should predict DDAGLV as a short extended/β-strand-like conformation with solvent-exposed aspartate side chains and a compact hydrophobic GLV face; pLDDT will likely be moderate (0.55-0.75) given the short length, but the backbone geometry should be consistent with an extended receptor-binding motif rather than a collapsed coil.","mechanism_class":null,"biohacker_use":null},"confidence":{"plddt":0.6354858875274658,"ptm":0.361372172832489,"iptm":0.6490685343742371,"chai_agreement":null,"chai1_gated_decision":"RAN_BORDERLINE","binding_probability":null,"binding_pic50":null,"predicted_binding_change":null},"profile":{"aggregation_propensity":0.0,"stability_score":0.5,"bbb_penetration_score":0.503,"half_life_estimate":"short (~15–45 minutes)"},"narrative":{"tldr":"FOLD №32 isolates the C-terminal hexapeptide DDAGLV from the 15-residue BPC-157 sequence to test whether this fragment alone constitutes a minimal VEGFR2-binding pharmacophore. The structural prediction yields a moderate pLDDT of 0.64 with a notably stronger ipTM of 0.65, suggesting the docked pose has internal consistency even if backbone confidence is only middling. The tandem aspartate orientation toward the receptor surface is promising, but a competing literature hypothesis assigns the active pharmacophore to the N-terminal proline-rich segment rather than this C-terminal fragment. The signal is interesting enough to pursue further but too ambiguous for a high-confidence verdict.","detailed_analysis":"BPC-157 (GEPPPGKPADDAGLV) is a synthetic 15-amino acid pentadecapeptide originally derived from human gastric juice that has attracted substantial preclinical interest for its tissue regenerative and pro-angiogenic properties. The mechanistic consensus, anchored primarily by Hsieh et al. (2017), positions VEGFR2 activation and downstream Akt-eNOS signaling as central to its biology. What remains entirely unresolved — and forms the intellectual basis of this fold — is which segment of the sequence is responsible for receptor engagement. No binding affinity measurements, no co-crystal structure, and no published truncation or alanine-scanning study exists for BPC-157 at any defined receptor target. FOLD №32 is, to our knowledge, the first computational truncation study specifically designed to interrogate this question.\n\nThe modification strategy is a fragment/truncation: residues 1–9 (GEPPPGKPA) are removed entirely, leaving only the six C-terminal residues DDAGLV. The hypothesis is that the tandem aspartates (D10–D11 in full-length numbering) mimic acidic VEGF-A loop residues that contact the VEGFR2 Ig-domain interface, and that the proline-rich N-terminal stretch is merely a conformationally flexible scaffold rather than a contact element. This is a direct and testable pharmacophore hypothesis, and the fragment-first approach is the most parsimonious way to probe it computationally before committing resources to synthesis.\n\nThe structural prediction supports a moderate level of optimism. The hexapeptide adopts an extended conformation consistent with the hypothesized β-strand-like receptor-docking geometry rather than a collapsed random coil — a meaningful positive signal given that short isolated fragments frequently lose ordered structure. The ipTM of 0.649 is the most interpretively important metric here: it reflects the internal consistency of the protein–peptide docked pose, and at this length a value near 0.65 indicates the interface geometry is not random. The backbone pLDDT of 0.636 is moderate, which is expected and appropriate for a hexapeptide; very high pLDDT values for sub-ten-residue peptides would themselves be suspicious. The pTM of 0.361 is lower, reflecting the challenge of confidently placing a tiny fragment in the overall structural ensemble, and should not be over-interpreted negatively.\n\nThe biological significance of the tandem aspartate motif is genuinely interesting. VEGF-A engages VEGFR2 through its β-hairpin loops, with acidic residue patches playing key contact roles at the Ig-domain interface. That BPC-157's only acidic residues are both concentrated in the C-terminal DDAGLV segment — rather than distributed across the full sequence — is structurally notable. The hydrophobic GLV tail could plausibly contribute to a shallow hydrophobic groove interaction of the type seen in short peptide–receptor docking. The predicted extended conformation, with aspartates oriented toward the receptor surface in the docked pose, is at least geometrically consistent with this hypothesis.\n\nHowever, the competing pharmacophore hypothesis must be taken seriously. The Schlosser preprint (2025, unreviewed) argues that the GEPPPGKPA segment adopts a polyproline II helix that engages SH3 domains of Src family kinases — a mechanistically coherent model given that PxxP motifs are canonical SH3 ligands. If this model is correct, the DDAGLV fragment is not a pharmacophore but a C-terminal appendage, and our truncation would produce a biologically inert fragment. The experimental data from Hsieh et al. does not resolve this: VEGFR2 activation could be downstream of SFK-mediated transactivation rather than direct extracellular ligand engagement. This ambiguity is the central limitation of the fold.\n\nHeuristic physicochemical properties add nuance. The stability score of 0.5 (moderate) and short predicted half-life (~15–45 minutes) indicate that DDAGLV, as a free hexapeptide, is likely susceptible to rapid proteolytic degradation in vivo — a concern compounded by the absence of the N-terminal proline-rich segment, which in the full-length peptide may provide some protease resistance through its polyproline geometry. The aggregation propensity of 0.0 is favorable and the BBB penetration estimate of 0.503 is marginally positive, though both are heuristic estimates with limited reliability for a fragment of this size. These properties do not disqualify the fragment but underscore that if DDAGLV shows any activity, metabolic stabilization would be the immediate next modification priority.\n\nThis fold connects thematically to the broader regenerative peptide work in this lab. The REFINED TB-500 fold (#28) demonstrated that even a seven-residue fragment can achieve strong structural confidence (pLDDT 0.81) when a macrocyclic constraint pre-organizes the conformation. The contrast is instructive: DDAGLV achieves moderate but meaningful docking confidence without any backbone constraint, which raises the question of whether a similar lactam bridge or staple — analogous to what worked in fold #28 — might pre-organize the DDAGLV fragment and boost both structural confidence and receptor affinity. That would be a logical follow-on fold if this signal strengthens.","executive_summary":"FOLD №32 predicts that BPC-157's C-terminal hexapeptide DDAGLV adopts an extended docking pose at VEGFR2 (ipTM 0.649), consistent with a minimal acidic pharmacophore hypothesis — but a competing preprint assigns activity to the N-terminal segment we removed, leaving the pharmacophore question genuinely open.","tweet_draft":"DISTILLATION №32 — promising.\nBPC-157 truncation: C-terminal hexapeptide DDAGLV vs. VEGFR2.\nipTM 0.649 | pLDDT 0.635 | extended docked conformation predicted.\nMinimal pharmacophore or inert fragment? Hypothesis open.\nIn silico only. Full report: alembic.bio","research_brief_markdown":"# FOLD №32 — BPC-157 C-Terminal Fragment DDAGLV for VEGFR2 Engagement\n**Verdict: PROMISING** | Peptide class: Regenerative | Target: VEGFR2 (KDR, P35968)\n\n---\n\n## Mechanism of Action\n\nBPC-157 (GEPPPGKPADDAGLV) is a 15-residue synthetic peptide derived from human gastric juice with broad preclinical tissue regenerative activity. Its best-characterized pro-angiogenic mechanism runs through VEGFR2: Hsieh et al. (2017, PMID:27847966) demonstrated that BPC-157 increases VEGFR2 mRNA and protein expression in human vascular endothelial cells, promotes dynamin-dependent receptor internalization, and activates the VEGFR2–Akt–eNOS signaling axis — without upregulating VEGF-A itself. This pattern is consistent with a ligand-mimicry model in which BPC-157 engages VEGFR2 directly, bypassing the endogenous growth factor. Downstream, VEGFR2–Akt–eNOS signaling promotes endothelial proliferation, migration, and nitric oxide-mediated vasodilation — mechanisms central to angiogenesis and tissue repair.\n\nA competing mechanistic model (Schlosser preprint, 2025, unreviewed) proposes that the N-terminal GEPPPGKPA segment adopts a polyproline II helix engaging SH3 domains of Src family kinases, with VEGFR2 activation occurring downstream via receptor transactivation rather than direct extracellular ligand engagement. This model is computationally derived and unvalidated by functional assays, but it is mechanistically coherent and must be held as a live alternative hypothesis.\n\n---\n\n## Modification Rationale\n\nFOLD №32 tests whether the C-terminal hexapeptide **DDAGLV** (residues 10–15 of BPC-157) constitutes a minimal pharmacophore sufficient for VEGFR2 engagement. The rationale has three elements:\n\n1. **Acidic residue pharmacophore hypothesis**: The tandem aspartates D10–D11 are the only acidic residues in the full 15-amino acid sequence and are concentrated entirely in the C-terminal DDAGLV fragment. VEGF-A contacts VEGFR2 primarily through β-hairpin loops bearing acidic patches; D10–D11 may mimic this chemistry at the Ig-domain interface.\n\n2. **N-terminal scaffold hypothesis**: The proline-rich GEPPPGKPA segment (residues 1–9) is conformationally flexible and may function as a non-pharmacophoric spacer rather than a receptor-contact element. Removing it should, on this hypothesis, expose the active motif rather than destroy it.\n\n3. **Fragment efficiency logic**: Isolating a minimal pharmacophore reduces molecular weight, potentially improves target selectivity, and creates a scaffold for subsequent optimization (cyclization, stapling, non-natural amino acid incorporation).\n\nThis approach diverges from folds #29–31 (Aib substitutions and a stapled peptide on other peptides) by introducing a fragment/truncation strategy with an affinity focus — the first such modification in this lab's BPC-157 series.\n\n---\n\n## Predicted Properties (Where Signal Is Moderate)\n\n| Metric | Value | Interpretation |\n|---|---|---|\n| pLDDT | 0.635 | Moderate backbone confidence; appropriate for hexapeptide length |\n| pTM | 0.361 | Low global fold confidence; expected given fragment size |\n| **ipTM** | **0.649** | **Strongest signal; indicates internally consistent docked pose** |\n| Predicted conformation | Extended / β-strand-like | Consistent with receptor-docking hypothesis; not collapsed coil |\n| Aggregation propensity | 0.0 | Favorable |\n| Stability score | 0.5 | Moderate; degradation risk is real |\n| Predicted half-life | ~15–45 min | Short; unprotected free hexapeptide |\n| BBB penetration (heuristic) | 0.503 | Marginally positive; low confidence for fragment this size |\n\nThe ipTM of 0.649 is the primary positive signal in this run. For a six-residue fragment docked to a large receptor, an ipTM approaching 0.65 indicates the interface geometry is non-random and has internal consistency across the prediction. The extended backbone conformation — with tandem aspartates appearing oriented toward the receptor surface and the GLV face forming a compact hydrophobic patch — is geometrically consistent with the ligand-mimicry hypothesis. This is not a confident binding prediction; it is a structurally plausible docked pose that warrants follow-up.\n\n---\n\n## What Would Strengthen This Signal\n\n**Computational next steps:**\n\n1. **Ensemble prediction**: Run DDAGLV vs. VEGFR2 across multiple seeds and sampling temperatures in AlphaFold3/Chai-1 to assess whether the extended conformation and ipTM ~0.65 are reproducible or run-specific. Single-run predictions at this confidence level cannot be interpreted without ensemble context.\n\n2. **Counter-fragment fold**: Predict the complementary N-terminal fragment GEPPPGKPA vs. VEGFR2 under identical conditions. If ipTM for the N-terminal fragment exceeds that of DDAGLV, the Schlosser SH3 model gains computational support and this truncation hypothesis is challenged. If GEPPPGKPA shows lower ipTM against VEGFR2 (but perhaps higher against a Src-SH3 domain), the pharmacophore assignment becomes cleaner.\n\n3. **Constrained DDAGLV variants**: A lactam-bridged or stapled DDAGLV — analogous to the i,i+3 lactam bridge used in TB-500 fold #28 (REFINED, pLDDT 0.81) — could pre-organize the extended conformation and potentially improve both pLDDT and ipTM. Fold #28 demonstrated clearly that macrocyclic constraints on short regenerative peptides can substantially boost structural confidence.\n\n4. **Alanine scan predictions**: Predict D1A-DAGLV and DD-A-GLV variants to assess whether each aspartate independently contributes to the docked pose geometry — a computational surrogate for classical alanine scanning.\n\n**Experimental validation (wet lab):**\n\n5. **Direct binding assay**: Surface plasmon resonance (SPR) or fluorescence polarization with synthesized DDAGLV and the VEGFR2 extracellular domain (Ig-domains 1–3) would definitively test whether this fragment binds. Given the complete absence of any published BPC-157 binding affinity data, even a negative result here would be a significant contribution to the field.\n\n6. **Cellular activity assay**: HUVEC tube formation and VEGFR2 phosphorylation (pY1175) assays comparing DDAGLV, full-length BPC-157, and the N-terminal GEPPPGKPA fragment would functionally map which segment drives downstream signaling.\n\n7. **Protease stability profiling**: Given the predicted short half-life (~15–45 min), a plasma stability assay on synthetic DDAGLV should precede any cell-based work to determine whether the fragment survives long enough to be biologically interpretable.\n\n---\n\n## Cross-Fold Connections\n\nThis fold sits within the lab's broader regenerative peptide programme alongside the TB-500 series (folds #7, #16, #28). The contrast with **fold #28** (TB-500 lactam bridge, REFINED, pLDDT 0.81) is instructive: that work demonstrated that macrocyclic pre-organization of a short regenerative heptapeptide can push structural confidence into the high-reliability range. DDAGLV achieves moderate docking confidence *without* any backbone constraint — which is either a genuine positive signal or an artefact of a permissive run. A constrained DDAGLV variant would test this directly and represents the most logical immediate next fold in this series.\n\n**Fold #16** (TB-500 Lys→Orn, DISCARDED) serves as a useful cautionary comparison: a single conservative substitution that seemed unlikely to disturb function nonetheless produced a biologically uninformative prediction. Fragment truncation is a far more aggressive modification than single-residue substitution, and the possibility that DDAGLV is simply a biologically inert fragment of a larger active scaffold cannot be excluded on the current data.","structural_caption":"The DDAGLV hexapeptide adopts a short extended conformation at the VEGFR2 interface, consistent with the hypothesized extended/β-strand-like geometry rather than a collapsed coil. The tandem aspartates appear oriented toward the receptor surface, while the GLV face provides a small hydrophobic patch. The interface ipTM (0.649) is the strongest signal in this run, indicating the docked pose is internally consistent, though the backbone confidence is only moderate.","key_findings_summary":"BPC-157 is a 15-amino acid pentadecapeptide (sequence: GEPPPGKPADDAGLV) originally isolated from human gastric juice that has demonstrated broad preclinical efficacy across tissue healing models. The most directly relevant mechanistic finding for our hypothesis comes from Hsieh et al. (2017, PMID:27847966), which is the primary peer-reviewed study establishing a direct link between BPC-157 and VEGFR2. This study demonstrated that BPC-157 increases VEGFR2 mRNA and protein expression in human vascular endothelial cells (without upregulating VEGF-A itself), promotes VEGFR2 internalization via endocytosis, and activates the downstream VEGFR2-Akt-eNOS signaling axis. Importantly, these effects were blocked by dynasore (an endocytosis inhibitor), suggesting receptor-mediated internalization is mechanistically central. This study is consistent with the hypothesis that BPC-157 engages VEGFR2 directly, but it does not resolve whether engagement is via an extracellular ligand-mimetic interaction or through indirect/intracellular mechanisms.\n\nA competing mechanistic hypothesis is proposed in the Schlosser preprint (2025, bioRxiv), which argues — based on in silico docking only — that BPC-157's proline-rich N-terminal segment (GEPPPGKPA) adopts a polyproline II (PPII) helix that engages SH3 domains of Src family kinases (c-Src, Yes, Fyn) intracellularly, with downstream activation of FAK-ERK and PI3K-Akt pathways. If this model is correct, the N-terminal proline-rich segment is not a 'flexible non-contributing scaffold' but rather the primary pharmacophore, and truncating it to isolate DDAGLV would ablate — rather than preserve — the key activity. This preprint is unreviewed and relies exclusively on computational modeling with an mCherry fusion protein validation, not functional VEGFR2 assays, so it must be weighted cautiously.\n\nThe broader literature (Seiwerth et al. 2021; McGuire et al. 2025; Gwyer et al. 2019) consistently positions BPC-157's pro-angiogenic effects as upstream of VEGFR2 signaling, supporting the VEGFR2 axis as genuinely relevant to its biology. McGuire et al. (2025) explicitly summarizes that BPC-157 'activates VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis.' However, none of these reviews provide structural data on which portion of the BPC-157 sequence mediates receptor contact, nor do any published studies report binding affinity measurements (Kd, IC50) for BPC-157 at VEGFR2 or any structural characterization of a BPC-157:VEGFR2 complex.\n\nWith respect to the specific hypothesis that tandem aspartates D10-D11 in DDAGLV mimic acidic VEGF-A loop residues contacting the VEGFR2 Ig-domain interface: no published study has tested this directly. VEGF-A contacts VEGFR2 primarily through its beta-hairpin loops, involving key residues including R82, E64, and acidic patches, but a systematic comparison with BPC-157's sequence has not been reported in the peer-reviewed literature. The structural premise is plausible but entirely untested, making this hypothesis novel but without direct experimental support or refutation in the existing literature."},"structured":{"known_activity":null,"known_binders":null,"candidate_variants":null,"domain_annotations":null,"literature_context":{"pubmed":[{"pmid":"40005999","title":"Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.","abstract":"BPC 157, known as the \"Body Protection Compound\", is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects in various preclinical models mimicking medical conditions, such as tissue injury, inflammatory bowel disease, or even CNS disorders. Unlike many other drugs, BPC 157 has a desirable safety profile, since only a few side effects have been reported following its administration. Nevertheless, this compound was temporarily banned by the World Anti-Doping Agency (WADA) in 2022 (it is not currently listed as banned by the WADA). However, it has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans. In this review, we summarize information on the biological activities of BPC 157, with particular reference to its mechanism of action and probable toxicity. This generated the attention of experts, as BPC 157 has been offered for sale on many websites. We also present recent interest in BPC 157 as reflected in a number of patent applications and granted patents.","authors":["Józwiak Michalina","Bauer Marta","Kamysz Wojciech","Kleczkowska Patrycja"],"year":2025,"journal":"Pharmaceuticals (Basel, Switzerland)"},{"pmid":"30915550","title":"Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.","abstract":"There is a current need for a therapy that can alleviate the social and economic burden that presents itself with debilitating and recurring musculoskeletal soft tissue injuries and disorders. Currently, several therapies are emerging and undergoing trials in animal models; these focus on the manipulation and administration of several growth factors implicated with healing. However, limitations include in vivo instability, reliance on biocompatible and robust carriers and restricted application procedures (local and direct). The aim of this paper is therefore to critically review the current literature surrounding the use of BPC 157, as a feasible therapy for healing and functional restoration of soft tissue damage, with a focus on tendon, ligament and skeletal muscle healing. Currently, all studies investigating BPC 157 have demonstrated consistently positive and prompt healing effects for various injury types, both traumatic and systemic and for a plethora of soft tissues. However, to date, the majority of studies have been performed on small rodent models and the efficacy of BPC 157 is yet to be confirmed in humans. Further, over the past two decades, only a handful of research groups have performed in-depth studies regarding this peptide. Despite this, it is apparent that BPC 157 has huge potential and following further development has promise as a therapy to conservatively treat or aid recovery in hypovascular and hypocellular soft tissues such as tendon and ligaments. Moreover, skeletal muscle injury models have suggested a beneficial effect not only for disturbances that occur as a result of direct trauma but also for systemic insults including hyperkalamia and hypermagnesia. Promisingly, there are few studies reporting any adverse reactions to the administration of BPC 157, although there is still a need to understand the precise healing mechanisms for this therapy to achieve clinical realisation.","authors":["Gwyer Daniel","Wragg Nicholas M","Wilson Samantha L"],"year":2019,"journal":"Cell and tissue research"},{"pmid":"40756949","title":"Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.","abstract":"Background: Body protection compound-157 (BPC-157) is a naturally occurring gastric peptide that promotes mucosal integrity and homeostasis. Preclinical studies show its potential for promoting healing in musculoskeletal injuries such as fractures, tendon ruptures, ligament tears, and muscle injuries. Despite lacking US Food and Drug Administration approval and its use being banned in professional sports, it is increasingly used by clinicians and athletes. Purpose: We sought to (1) provide a comprehensive synthesis of the BPC-157 literature from an orthopedic sports medicine perspective and (2) elucidate the mechanism of action, musculoskeletal effects, metabolism, and safety profile. Methods. We conducted a systematic review of English-language literature, published from database inception to June 3, 2024, from PubMed, Cochrane, and Embase. We searched PROSPERO to identify any current or unpublished reviews. Studies reporting BPC-157's mechanism, musculoskeletal outcomes, metabolism, and safety were included. Articles were screened in 3 phases by 2 reviewers. In cases of a disagreement between the 2 reviewers, blinding was removed, and eligibility was determined by group consensus, with a third author making the final decision. Results. A total of 544 articles from 1993 to 2024 were identified. After duplicates were removed, 36 studies were included (35 preclinical studies, 1 clinical study). The studies suggest that BPC-157 enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis, while reducing inflammatory cytokines. In preclinical models, BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries. In a retrospective study of musculoskeletal pain following intraarticular injection of BPC-157 for unspecified chronic knee pain, 7 of 12 patients reported relief for >6 months. BPC-157 is metabolized in the liver, with a half-life of less than 30 minutes, and is cleared by the kidneys. Preclinical safety studies showed no adverse effects across several organ systems. No clinical safety data were found. Conclusion: This systematic review of level IV and level V studies suggests that BPC-157 shows promise for promoting recovery from musculoskeletal injuries. Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety. We recommend that clinicians counsel athletes to understand their organizations' rules to remain compliant with medication/supplement safety and testing standards.","authors":["Vasireddi Nikhil","Hahamyan Henrik","Salata Michael J","Karns Michael","Calcei Jacob G","Voos James E","Apostolakos John M"],"year":2025,"journal":"HSS journal : the musculoskeletal journal of Hospital for Special Surgery"},{"pmid":"34267654","title":"Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.","abstract":"Significance: The antiulcer peptide, stable gastric pentadecapeptide BPC 157 (previously employed in ulcerative colitis and multiple sclerosis trials, no reported toxicity (LD1 not achieved)), is reviewed, focusing on the particular skin wound therapy, incisional/excisional wound, deep burns, diabetic ulcers, and alkali burns, which may be generalized to the other tissues healing. Recent Advances: BPC 157 has practical applicability (given alone, with the same dose range, and same equipotent routes of application, regardless the injury tested). Critical Issues: By simultaneously curing cutaneous and other tissue wounds (colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, and rectovaginal) in rats, the potency of BPC 157 is evident. Healing of the wounds is accomplished by resolution of vessel constriction, the primary platelet plug, the fibrin mesh which acts to stabilize the platelet plug, and resolution of the clot. Thereby, BPC 157 is effective in wound healing much like it is effective in counteracting bleeding disorders, produced by amputation, and/or anticoagulants application. Likewise, BPC 157 may prevent and/or attenuate or eliminate, thus, counteract both arterial and venous thrombosis. Then, confronted with obstructed vessels, there is circumvention of the occlusion, which may be the particular action of BPC 157 in ischemia/reperfusion. Future Directions: BPC 157 rapidly increases various genes expression in rat excision skin wound. This would define the healing in the other tissues, that is, gastrointestinal tract, tendon, ligament, muscle, bone, nerve, spinal cord, cornea (maintained transparency), and blood vessels, seen with BPC 157 therapy.","authors":["Seiwerth Sven","Milavic Marija","Vukojevic Jaksa","Gojkovic Slaven","Krezic Ivan","Vuletic Lovorka Batelja","Pavlov Katarina Horvat","Petrovic Andrea","Sikiric Suncana","Vranes Hrvoje","Prtoric Andreja","Zizek Helena","Durasin Tajana","Dobric Ivan","Staresinic Mario","Strbe Sanja","Knezevic Mario","Sola Marija","Kokot Antonio","Sever Marko","Lovric Eva","Skrtic Anita","Blagaic Alenka Boban","Sikiric Predrag"],"year":2021,"journal":"Frontiers in pharmacology"},{"pmid":"34324435","title":"Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.","abstract":"INTRODUCTION: Knee pain, a common complaint in primary care, has many causes, the most common of which is osteoarthritis (OA). Other common causes are meniscus tears, tendinosis, ligament tears or sprains, rheumatoid arthritis, lupus and septic arthritis. Also, referred pain from hip joint pathology like slipped capital femoral epiphysis can result in knee pain.1 The use of peptides BPC157 and thymosin-beta-4 (TB4) has not been studied in the treatment of knee pain.\n\nMETHODS: A retrospective study was done at the Institute for Hormonal Balance in Orlando, Florida, USA to see whether intra-articular injection of the peptide BPC 157, alone or combined with TB4, helped relieve knee pain. A 1-year chart review from 2019 to 2020 was performed. Since this was a retrospective study, patient follow-up varied, with most patients having had an injection of peptide into their knee 6 months to 1 year prior to the study. Of the 17 patients in the study, 16 were contacted by phone to follow up on the status of their knee pain. Only 1 patient could not be reached for the survey. Patients were asked to rate their pain prior to injection, the length of time the peptides helped ease the pain and the degree to which the injection helped them. No specific tools were used to measure their improvement in function, quality of life, stiffness or activities of daily living. The survey's main goal was to determine whether BPC157 helped with multiple types of knee pain in a primary care setting.\n\nRESULTS: Of the 16 patients, 12 had received only BPC 157 as an intra-articular injection. In this group, 11 of the 12 patients (91.6%) had significant improvement in knee pain, whereas 1 patient (8.3 %) had no improvement. The other 4 patients received a combination of 2 peptide injections of BPC 157 and TB4. Of the patients who received both peptides, 75% showed significant improvement, but 25% had no relief of their knee pain. Overall, 14 of 16 patients (87.5%) had relief of their knee pain when BPC 157 or a combination of BPC 157 and TB4 was used.\n\nCONCLUSION: This small study suggests that intra-articular injection of BPC-157 helps with multiple types of knee pain.\n\nCLINICAL IMPLICATIONS: BPC157 is a peptide with regenerative properties that can be used to relieve multiple types of knee pain.2,3 Future studies are needed to look at the different causes of knee pain with follow-up magnetic resonance imaging scans (MRIs) to document the peptide's benefits. BPC157 has the potential to repair tears, build cartilage and reduce the number of knee surgeries. Because of its reparative properties, treatment with BPC157 offers advantages over the use of steroids.\n\nRESULTS: BPC157 is a peptide with regenerative properties that can be used to relieve multiple types of knee pain.2,3 Future studies are needed to look at the different causes of knee pain with follow-up MRIs to document the peptide's benefits. BPC157 has the potential to repair tears, build cartilage and reduce the number of knee surgeries. Because of its reparative properties, treatment with BPC157 offers advantages over the use of steroids.","authors":["Lee Edwin","Padgett Blake"],"year":2021,"journal":"Alternative therapies in health and medicine"},{"pmid":"29998800","title":"BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.","abstract":"Commonly, the angiogenic growth factors signify healing. However, gastrointestinal ulceration is still poorly understood particularly with respect to a general pharmacological/pathophysiological role of various angiogenic growth factors implemented in growth factors wound healing concept. Thereby, we focused on the stable gastric pentadecapeptide BPC 157, a peptide given always alone vs. standard peptidergic angiogenic growth factors (EGF, FGF, VEGF), and numerous carriers. Further, we reviewed how the gastrointestinal tract healing could be generally perceived (i) in terms of angiogenic growth factors, and/or (ii) through the healing of extragastrointestinal tissues healing, such as tendon, ligament, muscle and bone, and vice versa. Respected were the beneficial effects obtained with free peptides or peptides with different carriers; EGF, FGF, VEGF, and BPC 157, their presentation along with injuries, and a healing commonality, providing their implementation in both gastrointestinal ulcer healing and tendon, ligament, muscle and bone healing. Only BPC 157 was consistently effective in all of the models of acute/chronic injury of esophagus, stomach, duodenum and lower gastrointestinal tract, intraperitoneally, per-orally or locally. Unlike bFGF-, EGF-, VEGF-gastrointestinal tract studies demonstrating improved healing, most of the studies on tendon, muscle and bone injuries provide evidence of their (increased) presentation along with the various procedures used to produce beneficial effects, compared to fewer studies in vitro, while in vivo healing has a limited number of studies, commonly limited to local application, diverse healing evidence with diverse carriers and delivery systems. Contrary to this, BPC 157 - using same regimens like in gastrointestinal healing studies - improves tendon, ligament and bone healing, accurately implementing its own angiogenic effect in the healing. Thus, we claim that just BPC 157 represents in practice a pharmacological and pathophysiological role of various peptidergic growth factors.","authors":["Seiwerth Sven","Rucman Rudolf","Turkovic Branko","Sever Marko","Klicek Robert","Radic Bozo","Drmic Domagoj","Stupnisek Mirjana","Misic Marija","Vuletic Lovorka Batelja","Pavlov Katarina Horvat","Barisic Ivan","Kokot Antonio","Japjec Mladen","Blagaic Alenka Boban","Tvrdeic Ante","Rokotov Dinko Stancic","Vrcic Hrvoje","Staresinic Mario","Sebecic Bozidar","Sikiric Predrag"],"year":2018,"journal":"Current pharmaceutical design"},{"pmid":"34380875","title":"Pentadecapeptide BPC 157 and the central nervous system.","abstract":"We reviewed the pleiotropic beneficial effects of the stable gastric pentadecapeptide BPC 157, three very recent demonstrations that may be essential in the gut-brain and brain-gut axis operation, and therapy application in the central nervous system disorders, in particular. Firstly, given in the reperfusion, BPC 157 counteracted bilateral clamping of the common carotid arteries-induced stroke, sustained brain neuronal damages were resolved in rats as well as disturbed memory, locomotion, and coordination. This therapy effect supports particular gene expression in hippocampal tissues that appeared in BPC 157-treated rats. Secondly, there are L-NG-nitro arginine methyl ester (L-NAME)- and haloperidol-induced catalepsy as well as the rat acute and chronic models of 'positive-like' schizophrenia symptoms, that BPC 157 counteracted, and resolved the complex relationship of the nitric oxide-system with amphetamine and apomorphine (dopamine agents application), MK-801 (non-competitive antagonist of the N-methyl-D-aspartate receptor) and chronic methamphetamine administration (to induce sensitivity). Thirdly, after rat spinal cord compression, there were advanced healing and functional recovery (counteracted tail paralysis). Likewise, in BPC 157 therapy, there is specific support for each of these topics: counteracted encephalopathies; alleviated vascular occlusion disturbances (stroke); counteracted dopamine disturbances (dopamine receptors blockade, receptors super sensitivity development, or receptor activation, over-release, nigrostriatal damage, vesicles depletion), and nitric oxide-system disturbances (\"L-NAME non-responsive, L-arginine responsive,\" and \"L-NAME responsive, L-arginine responsive\") (schizophrenia therapy); inflammation reduction, nerve recovery in addition to alleviated hemostasis and vessels function after compression (spinal cord injury therapy). Thus, these disturbances may be all resolved within the same agent's beneficial activity, i.e., the stable gastric pentadecapeptide BPC 157.","authors":["Vukojevic Jakša","Milavić Marija","Perović Darko","Ilić Spomenko","Čilić Andrea Zemba","Đuran Nataša","Štrbe Sanja","Zoričić Zoran","Filipčić Igor","Brečić Petrana","Seiverth Sven","Sikirić Predrag"],"year":2022,"journal":"Neural regeneration research"},{"pmid":"40789979","title":"Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.","abstract":"PURPOSE OF REVIEW: This scoping review aims to evaluate the molecular mechanisms, therapeutic potential, and safety concerns of Body Protective Compound-157 (BPC-157) in the context of musculoskeletal healing. Given the compound’s increasing availability, popularity, and its regulatory controversies, we sought to assess the breadth and quality of preclinical and clinical data supporting its use in musculoskeletal medicine.\n\nRECENT FINDINGS: BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and has demonstrated regenerative properties across numerous animal models. It activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization. It also engages ERK1/2 signaling, facilitates endothelial and muscle repair, and exerts anti-inflammatory effects. These effects promote angiogenesis, fibroblast activity, and neuromuscular stabilization, particularly in poorly vascularized tissues such as tendons and myotendinous junctions. Despite broad preclinical support, human data are extremely limited. Only three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics. No adverse effects were reported, but rigorous, large-scale trials are lacking.\n\nSUMMARY: BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, positioning it as a potentially valuable tool in musculoskeletal medicine. Despite its growing popularity among athletes and its wide availability through non-regulated sources, there is minimal human data available. Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution. This review highlights that given the robust preclinical evidence and high public interest, there is a critical need for well-designed human trials to assess the safety, efficacy, and clinical utility of BPC-157 in musculoskeletal medicine.","authors":["McGuire Flynn P","Martinez Riley","Lenz Annika","Skinner Lee","Cushman Daniel M"],"year":2025,"journal":"Current reviews in musculoskeletal medicine"},{"pmid":"27847966","title":"Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.","abstract":"UNLABELLED: BPC 157, a pentadecapeptide with extensive healing effects, has recently been suggested to contribute to angiogenesis. However, the underlying mechanism is not yet clear. The present study aimed to explore the potential therapeutic effect and pro-angiogenic mechanism of BPC 157. As demonstrated by the chick chorioallantoic membrane (CAM) assay and endothelial tube formation assay, BPC 157 could increase the vessel density both in vivo and in vitro, respectively. BPC 157 could also accelerate the recovery of blood flow in the ischemic muscle of the rat hind limb as detected by laser Doppler scanning, indicating the promotion of angiogenesis. Histological analysis of the hind limb muscle confirmed the increased number of vessels and the enhanced vascular expression of vascular endothelial growth factor receptor 2 (VEGFR2) in rat with BPC 157 treatment. In vitro study using human vascular endothelial cells further confirmed the increased mRNA and protein expressions of VEGFR2 but not VEGF-A by BPC 157. In addition, BPC 157 could promote VEGFR2 internalization in vascular endothelial cells which was blocked in the presence of dynasore, an inhibitor of endocytosis. BPC 157 time dependently activated the VEGFR2-Akt-eNOS signaling pathway which could also be suppressed by dynasore. The increase of endothelial tube formation induced by BPC 157 was also inhibited by dynasore. This study demonstrates the pro-angiogenic effects of BPC 157 that is associated with the increased expression, internalization of VEGFR2, and the activation of VEGFR2-Akt-eNOS signaling pathway. BPC 157 promotes angiogenesis in CAM assay and tube formation assay. BPC 157 accelerates the blood flow recovery and vessel number in rats with hind limb ischemia. BPC 157 up-regulates VEGFR2 expression in rats with hind limb ischemia and endothelial cell culture. BPC 157 promotes VEGFR2 internalization in association with VEGFR2-Akt-eNOS activation.\n\nKEY MESSAGE: BPC 157 promotes angiogenesis in CAM assay and tube formation assay. BPC 157 accelerates the blood flow recovery and vessel number in rats with hind limb ischemia. BPC 157 up-regulates VEGFR2 expression in rats with hind limb ischemia and endothelial cell culture. BPC 157 promotes VEGFR2 internalization in association with VEGFR2-Akt-eNOS activation.","authors":["Hsieh Ming-Jer","Liu Hsien-Ta","Wang Chao-Nin","Huang Hsiu-Yun","Lin Yuling","Ko Yu-Shien","Wang Jong-Shyan","Chang Vincent Hung-Shu","Pang Jong-Hwei S"],"year":2017,"journal":"Journal of molecular medicine (Berlin, Germany)"}],"biorxiv":[{"pmid":"","doi":"10.21203/rs.3.rs-8167242/v2","title":"BPC-157 Binding to SH3 Domains and Activation of Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Production","abstract":"<title>Abstract</title>  <p>  Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from human gastric juice with regenerative and cytoprotective effects reported across diverse tissues. Despite extensive preclinical study, the precise molecular mechanism underlying BPC-157's pleiotropic pro-repair effects remains incompletely understood. A key unresolved question is whether BPC-157 acts through extracellular receptor engagement, via intracellular interactions, or through a combination of both. Drawing on preclinical literature, structural modeling, and in silico docking, I propose that BPC-157 adopts a polyproline II helix that engages the Src homology 3 (SH3) domains of Src family kinases (SFKs; c-Src, Yes, Fyn). This interaction relieves SH3 domain-mediated autoinhibition of SFKs, resulting in focal adhesion kinase (FAK)-extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt) signaling cascades. To enable future experimental validation, a custom baculovirus encoding an engineered mCherry-BPC157  <sub>2</sub>  fusion protein was generated and used to transduce  <italic>Spodoptera frugiperda</italic>  (Sf9) cells. Expression of mCherry-BPC157  <sub>2</sub>  was validated by fluorescent imaging and confirmed by western blot at the expected molecular weight (~31 kDa). Collectively, this work proposes a novel structural and functional mechanism for BPC-157, provides in silico docking support, and introduces a molecular tool to probe the BPC-157 interactome.  </p>","authors":["SCHLOSSER SK."],"year":2025,"journal":"PPR","source":"PPR","preprint":true},{"pmid":"","doi":"10.21203/rs.3.rs-8167242/v1","title":"BPC-157 Predicted to Bind SH3 Domains and Activate Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Validation","abstract":"<title>Abstract</title>  <p>  Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from human gastric juice with regenerative and cytoprotective effects reported across diverse tissues. Despite extensive preclinical study, the precise molecular mechanism underlying BPC-157's pleiotropic pro-repair effects remains incompletely understood. A key unresolved question is whether BPC-157 acts through extracellular receptor engagement, via intracellular interactions, or through a combination of both. Drawing on preclinical literature, structural modeling, and in silico docking, I propose that BPC-157 adopts a polyproline II helix that engages the Src homology 3 (SH3) domains of Src family kinases (SFKs; c-Src, Yes, Fyn). This interaction relieves SH3 domain-mediated autoinhibition of SFKs, resulting in focal adhesion kinase (FAK)-extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt) signaling cascades. To enable future experimental validation, a custom baculovirus encoding an engineered mCherry-BPC157  <sub>2</sub>  fusion protein was generated and used to transduce Sf9 cells. Expression of mCherry-BPC157  <sub>2</sub>  was validated by fluorescent imaging and confirmed by western blot at the expected molecular weight (~31 kDa). Collectively, this work proposes a novel structural and functional mechanism for BPC-157, provides in silico docking support, and introduces a molecular tool to probe the BPC-157 interactome.  </p>","authors":["SCHLOSSER SK."],"year":2025,"journal":"PPR","source":"PPR","preprint":true},{"pmid":"","doi":"10.20944/preprints202512.1011.v3","title":"Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance","abstract":"Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel \"gray market\" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (Anti-Obesity Drug 9604), BPC-157 (Body Protection Compound 157), CJC-1295, FS-344 (Follistatin-344), GHK-Cu (Glycyl-L-histidyl-L-lysine copper), ipamorelin, MOTS-C (Mitochondrial ORF of the 12S rRNA type-c), sermorelin, SS-31 (Elamipretide), tesamorelin (Egrifta), Tβ4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment). Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data is scarce, and there is potential for serious harm to patients. This narrative review focuses on the utilization of peptides in sports medicine, and alternative treatments that may be considered. We provide a framework to navigate patient discussions about peptides to better facilitate evidence-based practices for musculoskeletal healing and athletic performance. We also discuss the placebo effect as a mediator of peptide efficacy, and how social media amplifies this effect.","authors":["Mendias CL","Awan TM."],"year":2026,"journal":"PPR","source":"PPR","preprint":true}],"preprints":[{"pmid":"","doi":"10.21203/rs.3.rs-8167242/v2","title":"BPC-157 Binding to SH3 Domains and Activation of Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Production","abstract":"<title>Abstract</title>  <p>  Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from human gastric juice with regenerative and cytoprotective effects reported across diverse tissues. Despite extensive preclinical study, the precise molecular mechanism underlying BPC-157's pleiotropic pro-repair effects remains incompletely understood. A key unresolved question is whether BPC-157 acts through extracellular receptor engagement, via intracellular interactions, or through a combination of both. Drawing on preclinical literature, structural modeling, and in silico docking, I propose that BPC-157 adopts a polyproline II helix that engages the Src homology 3 (SH3) domains of Src family kinases (SFKs; c-Src, Yes, Fyn). This interaction relieves SH3 domain-mediated autoinhibition of SFKs, resulting in focal adhesion kinase (FAK)-extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt) signaling cascades. To enable future experimental validation, a custom baculovirus encoding an engineered mCherry-BPC157  <sub>2</sub>  fusion protein was generated and used to transduce  <italic>Spodoptera frugiperda</italic>  (Sf9) cells. Expression of mCherry-BPC157  <sub>2</sub>  was validated by fluorescent imaging and confirmed by western blot at the expected molecular weight (~31 kDa). Collectively, this work proposes a novel structural and functional mechanism for BPC-157, provides in silico docking support, and introduces a molecular tool to probe the BPC-157 interactome.  </p>","authors":["SCHLOSSER SK."],"year":2025,"journal":"PPR","source":"PPR","preprint":true},{"pmid":"","doi":"10.21203/rs.3.rs-8167242/v1","title":"BPC-157 Predicted to Bind SH3 Domains and Activate Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Validation","abstract":"<title>Abstract</title>  <p>  Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from human gastric juice with regenerative and cytoprotective effects reported across diverse tissues. Despite extensive preclinical study, the precise molecular mechanism underlying BPC-157's pleiotropic pro-repair effects remains incompletely understood. A key unresolved question is whether BPC-157 acts through extracellular receptor engagement, via intracellular interactions, or through a combination of both. Drawing on preclinical literature, structural modeling, and in silico docking, I propose that BPC-157 adopts a polyproline II helix that engages the Src homology 3 (SH3) domains of Src family kinases (SFKs; c-Src, Yes, Fyn). This interaction relieves SH3 domain-mediated autoinhibition of SFKs, resulting in focal adhesion kinase (FAK)-extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt) signaling cascades. To enable future experimental validation, a custom baculovirus encoding an engineered mCherry-BPC157  <sub>2</sub>  fusion protein was generated and used to transduce Sf9 cells. Expression of mCherry-BPC157  <sub>2</sub>  was validated by fluorescent imaging and confirmed by western blot at the expected molecular weight (~31 kDa). Collectively, this work proposes a novel structural and functional mechanism for BPC-157, provides in silico docking support, and introduces a molecular tool to probe the BPC-157 interactome.  </p>","authors":["SCHLOSSER SK."],"year":2025,"journal":"PPR","source":"PPR","preprint":true},{"pmid":"","doi":"10.20944/preprints202512.1011.v3","title":"Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance","abstract":"Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel \"gray market\" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (Anti-Obesity Drug 9604), BPC-157 (Body Protection Compound 157), CJC-1295, FS-344 (Follistatin-344), GHK-Cu (Glycyl-L-histidyl-L-lysine copper), ipamorelin, MOTS-C (Mitochondrial ORF of the 12S rRNA type-c), sermorelin, SS-31 (Elamipretide), tesamorelin (Egrifta), Tβ4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment). Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data is scarce, and there is potential for serious harm to patients. This narrative review focuses on the utilization of peptides in sports medicine, and alternative treatments that may be considered. We provide a framework to navigate patient discussions about peptides to better facilitate evidence-based practices for musculoskeletal healing and athletic performance. We also discuss the placebo effect as a mediator of peptide efficacy, and how social media amplifies this effect.","authors":["Mendias CL","Awan TM."],"year":2026,"journal":"PPR","source":"PPR","preprint":true}],"consensus_view":"The literature consensus firmly supports that BPC-157 exerts pro-angiogenic effects through VEGFR2 upregulation and activation of the VEGFR2-Akt-eNOS signaling pathway. This is established primarily by one key experimental study (Hsieh et al., 2017) and reinforced by multiple subsequent reviews. However, there is no consensus — and virtually no primary data — regarding which structural segment of the 15-amino acid sequence is responsible for VEGFR2 engagement. The competing SH3-domain hypothesis (Schlosser preprint, 2025) assigns primacy to the N-terminal proline-rich segment, which directly contradicts our hypothesis. Whether BPC-157 acts as a direct extracellular VEGFR2 ligand or engages the receptor indirectly via intracellular signaling intermediates (e.g., SFK activation leading to transactivation of VEGFR2) remains entirely unresolved. The consensus is that VEGFR2 is involved but the pharmacophore is unknown.","knowledge_gaps":"The following critical gaps exist: (1) No published study has performed binding affinity measurements (SPR, ITC, fluorescence polarization) between BPC-157 and VEGFR2 or any defined receptor domain — the entire VEGFR2 engagement model is inferred from cellular signaling readouts, not direct binding data. (2) No structural data (NMR, X-ray crystallography, cryo-EM) exists for BPC-157 in complex with VEGFR2 or any receptor. (3) No sequence truncation or alanine-scanning mutagenesis study has been published that maps the pharmacophore of BPC-157 for any receptor target. (4) The specific claim that D10-D11 (tandem aspartates) mimic VEGF-A acidic loop residues has not been tested or even proposed in the peer-reviewed literature. (5) The conformational behavior of the C-terminal DDAGLV hexapeptide in isolation (whether it retains defined secondary structure without the N-terminal scaffold) is uncharacterized. (6) Whether VEGFR2 engagement by BPC-157 is extracellular or involves receptor transactivation via intracellular mechanisms has not been resolved experimentally.","supporting_evidence":"Hsieh et al. (2017) demonstrated that BPC-157 activates VEGFR2 without upregulating its ligand VEGF-A, which is consistent with the peptide acting as an independent VEGFR2-engaging molecule rather than stimulating autocrine VEGF release. The downstream signaling profile (Akt-eNOS activation, receptor internalization via dynamin-dependent endocytosis) matches the canonical VEGF-A/VEGFR2 signaling cascade, supporting the hypothesis that BPC-157 engages the same receptor machinery as VEGF-A and could plausibly use a ligand-mimicry mechanism. The presence of two consecutive aspartate residues (D10-D11) in the C-terminal DDAGLV segment is structurally notable given the known importance of acidic residues in VEGF-A:VEGFR2 contact interfaces. The hydrophobic C-terminal residues (A13, L14, V15) could plausibly contribute to a hydrophobic groove interaction analogous to those seen in peptide-growth factor receptor docking. The fact that BPC-157 is more consistently effective than exogenous VEGF across diverse models (Seiwerth et al., 2018) may suggest improved receptor engagement characteristics in vivo, a finding that would be consistent with a more direct, high-efficiency receptor-binding motif.","challenging_evidence":"The most significant challenge to our hypothesis comes from the Schlosser preprint (2025), which proposes — based on in silico PPII helix modeling — that the N-terminal GEPPPGKPA segment (residues 1-9, which we propose to truncate) is the primary active pharmacophore engaging SH3 domains of Src family kinases. If correct, removing this segment would destroy rather than improve activity. Although this preprint is unreviewed and computational only, the structural logic is sound: proline-rich motifs are canonical SH3 ligands, and the GEPPPGKP sequence conforms to the PxxP SH3-binding consensus. Furthermore, Hsieh et al. (2017) did not demonstrate direct extracellular binding of BPC-157 to VEGFR2 — VEGFR2 activation could be downstream of SFK-mediated transactivation, in which case the receptor engagement is indirect and the C-terminal DDAGLV fragment would be insufficient. No structure-activity relationship data in the published literature supports the C-terminal fragment as the active portion. The DDAGLV hexapeptide, lacking the N-terminal scaffold, may also be too conformationally flexible to adopt a receptor-docking geometry, as small peptide fragments frequently lose ordered structure when isolated from their sequence context. Additionally, the dynasore inhibition data from Hsieh et al. shows that receptor internalization is required for downstream signaling, raising the possibility that the mechanism of BPC-157 action involves intracellular rather than purely extracellular receptor engagement, further complicating a simple ligand-mimicry model."},"caveats":["in silico prediction only — requires wet lab validation","single-run prediction (not ensembled); ipTM 0.65 on a hexapeptide needs ensemble confirmation across multiple seeds","predicted properties may not reflect real-world biological behavior","this is research, not medical advice","fragment truncation removes the N-terminal proline-rich segment that an unreviewed preprint (Schlosser 2025) proposes as the primary pharmacophore — if that model is correct, DDAGLV is biologically inert and this prediction is misleading","no published binding affinity (Kd, IC50) or structural data exists for BPC-157 at VEGFR2; all mechanistic inferences are from cellular signaling readouts, not direct binding measurements","heuristic physicochemical values (half-life, BBB, stability, aggregation) are sequence-based estimates only — not experimental measurements; short hexapeptide fragments are particularly unreliable inputs for these heuristics","predicted short half-life (~15–45 min) suggests DDAGLV would require metabolic stabilization for any meaningful in vivo or cellular activity testing","pTM of 0.361 reflects low global structural confidence; only the ipTM metric is interpretively useful for this fragment-receptor prediction"],"works_cited":[{"pmid_or_doi":"27847966","title":"Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.","year":2017,"relevance":"The only primary experimental study directly linking BPC-157 to VEGFR2 activation; demonstrates upregulation of VEGFR2 expression, receptor internalization, and Akt-eNOS pathway activation, but does not identify which BPC-157 sequence segment mediates VEGFR2 engagement."},{"pmid_or_doi":"10.21203/rs.3.rs-8167242/v2","title":"BPC-157 Binding to SH3 Domains and Activation of Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Production","year":2025,"relevance":"Directly challenges the hypothesis by proposing the proline-rich N-terminal segment (GEPPPGKPA) — not the C-terminal DDAGLV — is the active pharmacophore, forming a PPII helix that engages SH3 domains; this is in silico only and unreviewed but is the most detailed structural mechanistic proposal available."},{"pmid_or_doi":"10.21203/rs.3.rs-8167242/v1","title":"BPC-157 Predicted to Bind SH3 Domains and Activate Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Validation","year":2025,"relevance":"Earlier version of the Schlosser preprint; same mechanistic argument that the N-terminal polyproline segment drives activity, relevant as a competing hypothesis to our C-terminal fragment approach."},{"pmid_or_doi":"40789979","title":"Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.","year":2025,"relevance":"Recent narrative review explicitly confirming VEGFR2 and Akt-eNOS axis as central to BPC-157 mechanism; also enumerates ERK1/2 engagement and notes the almost complete absence of human pharmacokinetic or receptor-binding structural data."},{"pmid_or_doi":"29998800","title":"BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.","year":2018,"relevance":"Contextualizes BPC-157 activity relative to canonical angiogenic growth factors (VEGF, FGF, EGF), noting BPC-157 is consistently effective where exogenous VEGF is not, suggesting mechanistic distinctiveness relevant to our receptor-mimicry hypothesis."},{"pmid_or_doi":"34267654","title":"Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.","year":2021,"relevance":"Documents rapid gene expression changes including vascular genes in BPC-157-treated tissue, consistent with VEGFR2-mediated transcriptional responses, though no sequence-activity data provided."},{"pmid_or_doi":"40005999","title":"Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.","year":2025,"relevance":"Comprehensive recent review summarizing the state of mechanism-of-action knowledge for BPC-157; confirms that precise receptor-binding pharmacophore remains uncharacterized in the literature."},{"pmid_or_doi":"30915550","title":"Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.","year":2019,"relevance":"Documents growth hormone receptor expression enhancement alongside VEGFR2 pathway involvement; relevant for understanding multi-receptor engagement context of the parent peptide."},{"pmid_or_doi":"40756949","title":"Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.","year":2025,"relevance":"Systematic review noting VEGFR2 upregulation as a confirmed mechanism; also notes the near-complete absence of human pharmacological or structural data, highlighting the knowledge gap our hypothesis addresses."},{"pmid_or_doi":"10.20944/preprints202512.1011.v3","title":"Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance","year":2026,"relevance":"Provides regulatory and pharmacological context for BPC-157 as an unapproved compound; notes lack of rigorous human data and absence of defined pharmacophore, supporting the rationale for our truncation study."}]},"onchain":{"hash":"rYRKJgM4QKR1FhyPCEPGDSFs8PVy1MaDM1rf1pZ2kRvC8Wa1hBksqUsxMfCtR4vMWX5mU4nw8t2apa58SoPVYsS","signature":"rYRKJgM4QKR1FhyPCEPGDSFs8PVy1MaDM1rf1pZ2kRvC8Wa1hBksqUsxMfCtR4vMWX5mU4nw8t2apa58SoPVYsS","data_hash":"7cc81949f67a7d079a29e6d61b614925bdcc9e0778b9b71f11a81c3f96209c31","logged_at":"2026-05-03T11:05:39.656977+00:00","explorer_url":"https://solscan.io/tx/rYRKJgM4QKR1FhyPCEPGDSFs8PVy1MaDM1rf1pZ2kRvC8Wa1hBksqUsxMfCtR4vMWX5mU4nw8t2apa58SoPVYsS"},"ipfs_hash":null,"created_at":"2026-05-03T10:56:14.596503+00:00","updated_at":"2026-05-03T11:05:39.663417+00:00"}